Advanced Biological Laboratories (ABL) and Roche Diagnostics International Signed a Collaboration Agreement to Promote their Next-Generation Sequencing, Genotyping and Drug Resistance Products Business Wire LUXEMBOURG -- September 10, 2013 Advanced Biological Laboratories (ABL) today announced the signing of a non-exclusive collaboration agreement with Roche Diagnostics International for Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories. This collaboration agreement is intended to develop a strategy to promote ABL products especially its next-generation sequencing platform DeepChek® together with Roche’s Next Generation Sequencing systems (GS Junior and GS FLX+ systems) for molecular virology. The principal objectives of the Collaboration are to provide our mutual customers with integrated sequencing and analysis systems delivering the required quality, sensitivity and meaningful genotyping and drug resistance reporting for personalized healthcare. About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. About ABL Advanced Biological Laboratories (ABL), S.A., is a biotech company founded in 2000 as a spin-off from the European academic research center, CRP-Santé Luxembourg and in 2004, acquired the control of TherapyEdge, Inc, a biotech company spin-off from Triangle Pharmaceuticals, Inc. and in 2013 acquired the Viral Hepatitis B & C related assets from EVIVAR MEDICAL, a biotech company spin-off from Melbourne Health in Australia. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek® and VisibleChek®, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, ABL's products received respectively CE-marking and IVD certifications. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. The clinical and biological outcomes aid in the generation of clinically meaningful genotyping reports for personalized healthcare. All trademarks used or mentioned in this release are protected by law. Contact: Advanced Biological Laboratories Dr Chalom Sayada, +352 2638 8921 CEO ABL SA
Advanced Biological Laboratories (ABL) and Roche Diagnostics International Signed a Collaboration Agreement to Promote their
Press spacebar to pause and continue. Press esc to stop.